Market Place
Sourcing Support
Protara Announces Closing of $100 Million Public Offering
11 Dec 2024 //
GLOBENEWSWIRE
Protara’s stock doubles biotech divulges new bladder cancer data
06 Dec 2024 //
FIERCE BIOTECH
Protara Therapeutics Hosts Call on Phase 2 ADVANCED-2 Trial Data
03 Dec 2024 //
GLOBENEWSWIRE
Protara to Present Phase 2 ADVANCED-2 Data in NMIBC 25th Meeting
15 Nov 2024 //
GLOBENEWSWIRE
Protara Announces Q3 2024 Results & Business Update
12 Nov 2024 //
GLOBENEWSWIRE
Protara Therapeutics to Present at Guggenheim Healthcare Conference
06 Nov 2024 //
GLOBENEWSWIRE
Protara Granted FDA Fast Track For Choline Chloride Treatment
21 Oct 2024 //
GLOBENEWSWIRE
Protara Announces Results From THRIVE-1 Study
09 Sep 2024 //
GLOBENEWSWIRE
Protara Completes First Cohort In STARBORN-1 Trial
09 Sep 2024 //
GLOBENEWSWIRE
Protara Therapeutics to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Protara Therapeutics Reports Q2 2024 Results And Business Update
06 Aug 2024 //
GLOBENEWSWIRE
Protara Therapeutics Reports Inducement Grant Under Nasdaq Rule 5635(c)(4)
24 Jun 2024 //
GLOBENEWSWIRE
Protara To Present At Cowen Oncology Innovation Summit
21 May 2024 //
GLOBENEWSWIRE
Protara Q1 2024 Results, Business Update
02 May 2024 //
GLOBENEWSWIRE
Protara Announces Positive Data from TARA-002 Clinical Program in NMIBC
05 Apr 2024 //
GLOBENEWSWIRE
Protara Announces Align with FDA on Reg Path Forward for IV Choline Chloride
05 Apr 2024 //
GLOBENEWSWIRE
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement
05 Apr 2024 //
GLOBENEWSWIRE
Protara Announces Fourth Quarter and Full Year 2023 Financial Results
13 Mar 2024 //
GLOBENEWSWIRE
Protara to Present at the TD Cowen 44th Annual Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
Protara Therapeutics to Participate in Upcoming Investor Conferences
31 Jan 2024 //
GLOBENEWSWIRE
Protara Announces Presentation of Data from Phase 1a Trial of TARA-002
30 Nov 2023 //
GLOBENEWSWIRE
Protara Therapeutics Announces Third Quarter 2023 Financial Results
03 Nov 2023 //
GLOBENEWSWIRE
Protara Announces Dosing of First Patient in Phase 2 Trial of TARA-002
23 Oct 2023 //
GLOBENEWSWIRE
Protara Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial
20 Sep 2023 //
GLOBENEWSWIRE
Protara to Present at H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
Protara Announces Second Quarter 2023 Financial Results and Business Update
03 Aug 2023 //
GLOBENEWSWIRE
Protara begins subject dosing in Phase Ib ADVANCED-1EXP expansion trial
16 May 2023 //
CLINICAL TRIALS ARENA
Protara Announces Dosing of 1st Patients in Ph 1b ADVANCED-1EXP Trial TARA-002
15 May 2023 //
GLOBENEWSWIRE
Protara Therapeutics Announces 1Q FYR 2023 and Business Update
04 May 2023 //
GLOBENEWSWIRE
Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Ph2
02 May 2023 //
GLOBENEWSWIRE
Protara Announces Fourth Quarter and Full Year 2022 Financial Results
08 Mar 2023 //
GLOBENEWSWIRE
Protara Therapeutics to Participate in Upcoming Investor Conferences
01 Mar 2023 //
GLOBENEWSWIRE
Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
02 Feb 2023 //
GLOBENEWSWIRE
Protara Announces Appointment of Patrick Fabbio as Chief Financial Officer
30 Jan 2023 //
GLOBENEWSWIRE
Protara Announces Trials Progress Poster Presentation for the ADVANCED-1 Trial
01 Dec 2022 //
GLOBENEWSWIRE
Protara Therapeutics Announces 3Q FYR and Business Overview
03 Nov 2022 //
GLOBENEWSWIRE
Protara Therapeutics Announces Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Protara Therapeutics Announces Departure of Chief Financial Officer
21 Jun 2022 //
GLOBENEWSWIRE
Protara Tx Announces Trials in Poster Presentation for ADVANCED-1 Trial in NMIBC
26 May 2022 //
GLOBENEWSWIRE
Protara Therapeutics to Present at H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
Protara Therapeutics Presents Results from Retrospective Analysis of OK-432
12 May 2022 //
GLOBENEWSWIRE
Protara Therapeutics Announces First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Protara Tx Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002
24 Mar 2022 //
GLOBENEWSWIRE
Protara Tx says Q4 and FY 2021 Financial Results
09 Mar 2022 //
GLOBENEWSWIRE
Protara Therapeutics to Participate in Upcoming Investor Conferences
02 Mar 2022 //
GLOBENEWSWIRE
Protara Announces Q3 2021 Financial Results and Business Overview
04 Nov 2021 //
GLOBENEWSWIRE
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq
25 Oct 2021 //
GLOBENEWSWIRE
Protara Announces FDA Clearance of InG New Drug Application for TARA-002
12 Oct 2021 //
GLOBENEWSWIRE
Protara Therapeutics Announces FDA Clearance Of INDA For TARA-002
12 Oct 2021 //
BENZINGA
Protara to Present at Oppenheimer Fall Healthcare Life Sciences, MedTech Summit
17 Sep 2021 //
GLOBENEWSWIRE
Protara Therapeutics Announces Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
07 Jul 2021 //
GLOBENEWSWIRE
Protara Therapeutics Provides Regulatory Update for TARA-002
23 Apr 2021 //
GLOBENEWSWIRE
Protara Therapeutics Provides Comparability & Regulatory Updates for TARA-002
08 Sep 2020 //
BIOSPACE
